Acacia Research (ACTG) Reaches $3.95 52-Week Low, 3 Analysts Covering Phibro Animal Health (PAHC)

June 12, 2017 - By Adrian Mccoy

Among 7 analysts covering Philbro Animal Health (NASDAQ:PAHC), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Philbro Animal Health had 10 analyst reports since September 30, 2015 according to SRatingsIntel. The stock has “Underweight” rating by Barclays Capital on Monday, January 18. The company was initiated on Thursday, December 15 by Piper Jaffray. The rating was initiated by Credit Suisse on Thursday, February 4 with “Outperform”. The firm has “Hold” rating given on Friday, June 2 by Credit Suisse. As per Thursday, November 10, the company rating was downgraded by Gabelli. The company was downgraded on Friday, January 15 by Barclays Capital. The firm has “Underperform” rating by Macquarie Research given on Friday, November 11. The stock of Phibro Animal Health Corp (NASDAQ:PAHC) has “Overweight” rating given on Tuesday, October 13 by KeyBanc Capital Markets. The stock of Phibro Animal Health Corp (NASDAQ:PAHC) has “Buy” rating given on Wednesday, September 30 by Gabelli. See Phibro Animal Health Corp (NASDAQ:PAHC) latest ratings:

02/06/2017 Broker: Credit Suisse Rating: Hold New Target: $36.0000 Downgrade
15/12/2016 Broker: PiperJaffray Rating: Overweight New Target: $32.00 Initiates Coverage On
15/12/2016 Broker: Piper Jaffray Rating: Overweight Initiate

The stock of Acacia Research Corp (NASDAQ:ACTG) hit a new 52-week low and has $3.83 target or 3.00% below today’s $3.95 share price. The 5 months bearish chart indicates high risk for the $209.81M company. The 1-year low was reported on Jun, 12 by Barchart.com. If the $3.83 price target is reached, the company will be worth $6.29M less. The stock decreased 5.95% or $0.25 during the last trading session, reaching $3.95. About 322,954 shares traded. Acacia Research Corp (NASDAQ:ACTG) has declined 3.02% since June 12, 2016 and is downtrending. It has underperformed by 19.72% the S&P500.

Among 3 analysts covering Acacia Research (NASDAQ:ACTG), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Acacia Research has $12 highest and $4 lowest target. $5.97’s average target is 51.14% above currents $3.95 stock price. Acacia Research had 6 analyst reports since August 20, 2015 according to SRatingsIntel. Barclays Capital downgraded Acacia Research Corp (NASDAQ:ACTG) on Tuesday, January 5 to “Underweight” rating. As per Friday, July 29, the company rating was maintained by Barclays Capital. The firm earned “Buy” rating on Wednesday, December 23 by Lake Street. The stock has “Outperform” rating by Northland Capital on Monday, May 23.

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.06, from 1.14 in 2016Q3. It improved, as 12 investors sold Acacia Research Corp shares while 34 reduced holdings. 22 funds opened positions while 33 raised stakes. 37.16 million shares or 0.86% less from 37.48 million shares in 2016Q3 were reported. Renaissance Techs accumulated 3.40M shares. Deprince Race Zollo has invested 0% of its portfolio in Acacia Research Corp (NASDAQ:ACTG). Spark Inv Mgmt Lc stated it has 0.12% in Acacia Research Corp (NASDAQ:ACTG). Moreover, Federated Investors Inc Pa has 0% invested in Acacia Research Corp (NASDAQ:ACTG) for 2,529 shares. Chicago Equity Prtn Ltd Liability Co reported 159,720 shares stake. Invesco Limited owns 136,010 shares for 0% of their portfolio. Davenport & Llc reported 0% stake. Thompson Davis has 0% invested in Acacia Research Corp (NASDAQ:ACTG) for 500 shares. Heartland Advsr Incorporated has 1.71% invested in Acacia Research Corp (NASDAQ:ACTG). Morgan Stanley, New York-based fund reported 402,720 shares. Raymond James & Assocs holds 0% or 30,440 shares. Princeton Alpha Mgmt Lp invested 0.03% of its portfolio in Acacia Research Corp (NASDAQ:ACTG). Illinois-based Northern Tru Corporation has invested 0% in Acacia Research Corp (NASDAQ:ACTG). Blackrock invested in 10,182 shares. Systematic Mngmt Lp reported 234,720 shares or 0.02% of all its holdings.

Acacia Research Corporation, through its subsidiaries, invests in, licenses and enforces patented technologies. The company has market cap of $209.81 million. The Company’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. It currently has negative earnings. The Company’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.

Since March 10, 2017, it had 5 insider purchases, and 0 selling transactions for $1.00 million activity. GRAZIADIO G LOUIS III had bought 97,445 shares worth $485,851 on Thursday, May 11. $227,758 worth of stock was bought by Walsh Frank E. III on Friday, March 10.

Since December 19, 2016, it had 0 buys, and 29 sales for $18.32 million activity. 5,000 shares were sold by Welch Daniel A, worth $141,500 on Monday, February 27. Another trade for 48,000 shares valued at $1.64 million was made by BFI Co. – LLC on Wednesday, May 17. Dagger Thomas G sold 12,200 shares worth $436,272. Miller Larry Lee sold $53,822 worth of stock. Carlson Gerald K sold $339,480 worth of Phibro Animal Health Corp (NASDAQ:PAHC) on Monday, February 27. BENDHEIM JACK sold 48,000 shares worth $1.64 million. 10,000 shares valued at $335,400 were sold by Warras Dean J on Thursday, May 11.

About 94,238 shares traded. Phibro Animal Health Corp (NASDAQ:PAHC) has risen 89.87% since June 12, 2016 and is uptrending. It has outperformed by 73.17% the S&P500.